Vericel Corp
NASDAQ:VCEL
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
32.52
59.11
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Gross Margin
Vericel Corp
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Gross Margin Across Competitors
Country | US |
Market Cap | 2.9B USD |
Gross Margin |
71%
|
Country | FR |
Market Cap | 6T USD |
Gross Margin |
0%
|
Country | US |
Market Cap | 320.1B USD |
Gross Margin |
67%
|
Country | US |
Market Cap | 147.4B USD |
Gross Margin |
60%
|
Country | US |
Market Cap | 119.4B USD |
Gross Margin |
86%
|
Country | US |
Market Cap | 113.8B USD |
Gross Margin |
78%
|
Country | US |
Market Cap | 94.1B EUR |
Gross Margin |
76%
|
Country | AU |
Market Cap | 135.4B AUD |
Gross Margin |
52%
|
Country | US |
Market Cap | 82.6B USD |
Gross Margin |
87%
|
Country | US |
Market Cap | 39.3B EUR |
Gross Margin |
75%
|
Country | NL |
Market Cap | 34.3B EUR |
Gross Margin |
89%
|
Vericel Corp
Glance View
Vericel Corp. engages in the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of patients with diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 281 full-time employees. The firm is focused on therapies for the sports medicine and severe burn care markets. The company markets two autologous cell therapy products in the United States, which include MACI (autologous cultured chondrocytes on porcine collagen membrane) and Epicel (cultured epidermal autografts). MACI is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel is a permanent skin replacement humanitarian use device (HUD) for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns comprising greater than or equal to 30% of total body surface area (TBSA). Its NexoBrid, is a registration-stage, topically administered biological product that enzymatically removes nonviable burn tissue, or eschar, in patients with deep partial and full-thickness thermal burns.
See Also
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Based on Vericel Corp's most recent financial statements, the company has Gross Margin of 71.5%.